Research assistance

We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 

Matching geography

Reports matching your search in:
 
 

Join Alert Me now!

Receive bi-weekly email alerts on new market research

Sign up today!
 

Manufacturing, Packaging & Detailing: reports

1594

Both prescription and over-the-counter (OTC) drugs must be manufactured in accordance with standards established by the Food and Drug Administration (FDA). The agency inspects manufacturing facilities before a drug application can be approved. Any manufacturing deficiencies found would need to be corrected before approval.

Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA.

The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.

Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.

The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.

  • Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
  • Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
  • Use of checkweighers and sorters
  • Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
  • Use of quality control labeling systems

It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.

RSS Feeds

Manufacturing, Packaging & Detailing market research reports and industry analysis

< prev 1  2  3  4  5  6  7  8  9  10  next >
Zambia Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... by both NGOs and international investors as a sign that Zambia istaking its commitment to healthcare seriously. The country suffers from a burden of both communicableand non-communicable diseases, with a high incidence of HIV and ...  |  more...
$1,175.00
Qatar Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... is anticipated the drug manufacturers will (in our view eventually) help curbreliance on imports and lower prices of retail medicines in the country as a result of increased localcompetition, according to Dr Aisha al-Ansari of ...  |  more...
$1,175.00
Brazil Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... and pharmaceutical industry to reduce thefinancial burden of diseases, and the country's private healthcare sectors provide opportunities forforeign companies. However, the increasing drug rebate level has significantly undermined the profitsrecorded by generic drugmakers. The more ...  |  more...
$1,175.00
Romania Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... are a small improvement, though definitely not what producerswould have wanted ideally. With part of the objective of the claw-back tax to improve the timeliness ofpayments for reimbursed medicines, which has been a major difficulty ...  |  more...
$1,175.00
Central America Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... opportunities forgeneric drugmakers from neighbouring Latin American countries and India. We highlight that Costa Ricaand Panama can be the premier countries in the region for foreign drugmakers to expand their presence. Headline Expenditure Projections Pharmaceuticals: ...  |  more...
$1,175.00
Lithuania Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... with the market expected to increase by a local currency margin of 2.5%year-on-year (y-o-y) to reach LTL1.68bn (US$618mn) in 2012 at consumer prices. However, in US dollarterms, the market's value will shrink by 6.3%, indicating ...  |  more...
$1,175.00
Portugal Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... Portugal has already made considerable savings in the healthcaresectors, with changes such as the introduction of e-prescriptions and prescribing by active ingredients,changes to reference pricing, reductions in pharmacy margins and price cuts just some of ...  |  more...
$1,175.00
Serbia Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... consumption is also expected to rise. However, financial inefficiencies within the healthinsurance system mean that the National Health Insurance Institution (RZZO) is unable to always meet itsobligations on time, leaving patients to pay for formerly ...  |  more...
$1,175.00
Hungary Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... margins and introduced insecurityto an already difficult economic environment, and we continue to expect a contraction in the size of theHungarian pharmaceutical market in 2012 and 2013. Consequently, Hungarian drugmakers will have tobecome even more ...  |  more...
$1,175.00
Morocco Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... the evidence ofbribery and corruption, and the shortage of doctors in the sector. BMI believes the commitment toimprove governance and implement controls in the sector will be fulfilled in the medium-to-long term. Assuch, we maintain ...  |  more...
$1,175.00
Jordan Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... generic medicines, in tandem withprice-reduction strategies. Nevertheless, the expansion of government provision and the higher uptake ofgeneric medicines will conspire to keep longer term growth steady, boosted by upward volume changes,with the patented drug market ...  |  more...
$1,175.00
Slovakia Pharmaceuticals and Healthcare Report Q1 2013
1/16/2013 | published by: Business Monitor International
... this is realised. We do not expect either of the two private insurers - Dôvera or DutchownedUnion - will surrender their businesses without a fight, with Union in particular well-placedto oppose the move, potentially invoking ...  |  more...
$1,175.00
Indonesia Pharmaceuticals & Healthcare Industry 2H12
1/14/2013 | published by: Emerging Markets Direct Reports
... support and pharmaceutical trade. It also covers the market trends and outlook, regulatory changes, counterfeit drugs, industry SWOT analysis and market outlook, plus profile, comparative matrix and SWOT analysis of the leading players: PT Kalbe ...  |  more...
$450.00
Switzerland Pharmaceuticals and Healthcare Report Q1 2013
1/9/2013 | published by: Business Monitor International
... believes the government needs to do more to alter patients' attitudestowards these drugs as this is the main growth deterrent. Headline Expenditure Projections Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% declinein ...  |  more...
$1,175.00
Sudan and South Sudan Pharmaceuticals and Healthcare Report Q1 2013
1/2/2013 | published by: Business Monitor International
... non-oil economies. Political risk remains elevated as many disputesbetween them are still unresolved. These macroeconomic uncertainties will mean lack of focus on publichealthcare provision, which further complicates the problem that the general population are unable ...  |  more...
$1,175.00
Ukraine Pharmaceuticals and Healthcare Report Q1 2013
1/2/2013 | published by: Business Monitor International
... represent a very large business risk for internationaldrugmakers operating in the country. While Ukraine remains one of Central and Eastern Europe (CEE)'smore promising pharmaceutical markets given its favourable demographics and disease profile, itschronic lack of ...  |  more...
$1,175.00
Poland Pharmaceuticals and Healthcare Report Q1 2013
1/2/2013 | published by: Business Monitor International
... has shifted towards the Polishconsumer, as the harsher reimbursement regime has caused private contributions to prescriptionpayments rise. We forecast a return to growth in 2013, driven by private consumption as the Polishgovernment entrenches cuts to ...  |  more...
$1,175.00
Gabon Pharmaceuticals and Healthcare Report Q1 2013
1/2/2013 | published by: Business Monitor International
... and the vast majority of expenditure will be on low-marginessential medicines. Due to tepid economic growth, our outlook for Gabon's pharmaceutical market isbelow that expected to be posted by many of its sub-Saharan Africa neighbours. ...  |  more...
$1,175.00
Botanical and Plant-Derived Drugs: Global Markets
1/1/2013 | published by: BCC Research
... from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017 A focus on legal, prescription-required therapeutic medicines sold in the open market; the study does not specifically cover herbals generally ...  |  more...
$4,850.00
Healthcare, Regulatory and Reimbursement Landscape - Jordan
1/1/2013 | published by: GlobalData
... an analysis of the healthcare, regulatory and reimbursement landscape of Jordan. The report identifies the key trends in the healthcare market of Jordan. The report also provides insights on the demographic, regulatory, reimbursement landscape and ...  |  more...
$1,995.00
325412 Pharmaceutical Preparation Manufacturing: State Industry Market Evaluator
12/31/2012 | published by: BizMiner
... volume, average firm, site and small business sales, sales per employee, market volume by employment class, employment by employment class and more. Additional statistics include failure rates (firms, establishments, small business, startups). startup activity rates ...  |  more...
$699.00
325414 Biological Product (Except Diagnostic) Manufacturing: State Industry Market Evaluator
12/31/2012 | published by: BizMiner
... volume, average firm, site and small business sales, sales per employee, market volume by employment class, employment by employment class and more. Additional statistics include failure rates (firms, establishments, small business, startups). startup activity rates ...  |  more...
$699.00
541711.03 Biological Product Research: State Industry Market Evaluator
12/31/2012 | published by: BizMiner
... volume, average firm, site and small business sales, sales per employee, market volume by employment class, employment by employment class and more. Additional statistics include failure rates (firms, establishments, small business, startups). startup activity rates ...  |  more...
$699.00
3254 Pharmaceutical and Medicine Manufacturing: State Industry Market Evaluator
12/31/2012 | published by: BizMiner
... volume, average firm, site and small business sales, sales per employee, market volume by employment class, employment by employment class and more. Additional statistics include failure rates (firms, establishments, small business, startups). startup activity rates ...  |  more...
$699.00
Healthcare, Regulatory and Reimbursement Landscape - South Africa
12/28/2012 | published by: GlobalData
... the South African healthcare, regulatory and reimbursement landscape, this report identifies the key trends in the healthcare market, as well as providing insights on the demographic, regulatory, and reimbursement landscape and healthcare infrastructure. Most importantly, ...  |  more...
$1,995.00
< prev 1  2  3  4  5  6  7  8  9  10  next >